Irradiation of regional nodes in breast cancer patients affects overall survival
the ONA take:
Irradiation of regional nodes in patients with stage I-III breast cancer has a minimal effect on overall survival, according to a recent study published in The New England Journal of Medicine; however, irradiation improved disease-free survival, distant-disease-free survival, and breast cancer mortality.
For the phase III trial, researchers enrolled 4,004 patients with positive axillary lymph nodes, or centrally or medially located primary tumors with negative lymph nodes. Patients were randomly assigned to receive whole-breast or thoracic-wall irradiation plus regional nodal irradiation or whole-breast or thoracic-wall irradiation alone.
Results showed that regional irradiation benefits patients with early stage breast cancer and acute adverse events associated with regional irradiation were modest.
However, the authors note that these results do not apply to patients with laterally located node-negative cancers, which represent the largest patient subgroup of early-stage breast cancers in first-world countries. The investigators plan to continue monitoring patients for a median follow-up of 20 years.
Irradiation of regional nodes in patients with stage I-III breast cancer has a minimal effect on overall survival.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|